Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07711171 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment

Name: Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment — clinical trial record (NCT07711171)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorFudan University

Started2024-08-19

View on ClinicalTrials.gov ↗

Fudan University

624 trials monitored

See 9 trials at risk

Diabetes

4,247 trials monitored

See 176 trials at risk

Type 2 Diabetes

2,082 trials monitored

See 101 trials at risk

The prevalence of cognitive dysfunction in diabetic patients is high, which seriously affects the quality of life of patients, and early intervention is of great significance. Central nervous system insulin resistance plays a key role in the pathogenesis of cognitive dysfunction in diabetic patients. Central insulin resistance observed by functional magnetic resonance imaging (fMRI), may serve as an alternative endpoint for assessing cognitive function. Sodium glucose cotransporter 2 inhibitor (SGLT2i) may improve cognitive impairment by improving central insulin resistance.

Trial Details

NCT Number	NCT07711171
Lead Sponsor	Fudan University
Conditions	Type 2 Diabetes Mellitus, Cognitive Impairment
Enrollment	60 participants
Start Date	2024-08-19
Primary Completion	2026-10-30 (estimated)
Study Completion	2026-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-17